Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tasly’s Modernized TCMs To Be Included In South African Medical Insurance

This article was originally published in PharmAsia News

Executive Summary

Tianjin Tasly Group's seven modernized traditional Chinese medicines including Cardiotonic Pill have been confirmed as procurement products by the South African government for its medical insurance catalog. The China firm, in pursuing a globalization strategy, set up its South African branch in 2002 and has since seen its sales in the continent soar from $100,000 to an impressive $80 million in 2007. Cardiotonic Pill, Tasly's key product, has completed trademark registration in 34 countries and regions. The medicine is currently undergoing FDA and EMEA Phase ? and ? clinical trials. Tasly is using this opportunity to promote TCM, especially modernized traditional medicines, and gain entry into the mainstream market of developed countries. (Click here for more - Chinese language)

You may also be interested in...



Siemens Healthineers Gets Varian In 16.4Bn Deal To Enter Cancer Treatment Market

In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.

Coronavirus Update: Russia Plans First Vaccinations In October

Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.

Sun Loses Shine In Q1, Testing Times In US

Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel